ProCE Banner Activity

The Activity and Safety of First-Generation TRK Inhibitors in NTRK Fusion–Positive Cancers

Slideset Download
Download these expert-selected slides on treating patients with NTRK-positive tumors with TRK inhibitors.

Released: June 11, 2021

Expiration: June 10, 2022

No longer available for credit.

Share

Faculty

Alexander Drilon

Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Genentech, a member of the Roche Group

Faculty Disclosure

Primary Author

Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York